Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **ricin A chain–B chain disulfide bond** is a single covalent linkage that joins the enzymatically active A chain (RTA) to the cell-binding B chain (RTB) of the heterodimeric plant toxin ricin[4][5]. Upon cellular uptake, reduction of this disulfide bond in the endoplasmic reticulum is a critical step that releases the A chain into the cytosol[3][4][5]. The free A chain then catalyzes the depurination of a specific adenine residue in the 28S rRNA of eukaryotic ribosomes, halting protein synthesis and leading to cell death[1][3][4]. The disulfide bond itself is not a therapeutic target, but its cleavage is essential for ricin's mechanism of action; thus, the term "ricin disulfide bond cleavage" refers to a step in ricin toxicity and not an independent receptor, enzyme, or molecular target.
Disulfide bond reduction releases the enzymatic A chain to enter the cytosol and inhibit protein synthesis[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ricin A chain–B chain disulfide bond.